Patents by Inventor James R. MANNING

James R. MANNING has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250011334
    Abstract: The invention provides compounds of Formula (1): as further described herein, as well as pharmaceutical compositions comprising such compounds, and methods to use the compounds and pharmaceutical compositions for treatment of certain viral disorders, including influenza.
    Type: Application
    Filed: June 13, 2024
    Publication date: January 9, 2025
    Inventors: Rama JAIN, Dennis Christofer KOESTER, James R. MANNING, Vanessa MARX, Daniel POON, James Clifford SUTTON, Benjamin R. TAFT, Lifeng WAN, Aregahegn YIFRU, Qian ZHAO
  • Publication number: 20250002479
    Abstract: The present disclosure relates to compounds of formula (I) and pharmaceutical compositions and their use in reducing Widely Interspaced Zinc Finger Motifs (WIZ) expression levels, or inducing fetal hemoglobin (HbF) expression, and in the treatment of inherited blood disorders (e.g., hemoglobinopathies, e.g., beta-hemoglobinopathies), such as sickle cell disease and beta-thalassemia.
    Type: Application
    Filed: September 6, 2024
    Publication date: January 2, 2025
    Inventors: Simone BONAZZI, Jennifer Stroka COBB, Natalie Alysia DALES, Matthew James HESSE, Rama JAIN, John Ryan KERRIGAN, Hasnain Ahmed MALIK, James R. MANNING, Pamela YF TING
  • Publication number: 20240158374
    Abstract: The present disclosure relates to compounds of formula (I) and pharmaceutical compositions and their use in reducing Widely Interspaced Zinc Finger Motifs (WIZ) expression levels, or inducing fetal hemoglobin (HbF) expression, and in the treatment of inherited blood disorders (e.g., hemoglobinopathies, e.g., beta-hemoglobinopathies), such as sickle cell disease and beta-thalassemia.
    Type: Application
    Filed: September 1, 2023
    Publication date: May 16, 2024
    Inventors: Simone BONAZZI, Artiom CERNIJENKO, Jennifer Stroka COBB, Natalie Alysia DALES, Janetta DEWHURST, Matthew James HESSE, Rama JAIN, John Ryan KERRIGAN, Hasnain Ahmed MALIK, James R. MANNING, Gary O'BRIEN, Andrew W. PATTERSON, Noel Marie-France THOMSEN, Pamela YF TING
  • Publication number: 20220363671
    Abstract: Described herein are glue degrader compounds, their various targets, their preparation, pharmaceutical compositions comprising them, and their use in the treatment or prevention of conditions, diseases, and disorders mediated by various target proteins.
    Type: Application
    Filed: September 16, 2020
    Publication date: November 17, 2022
    Inventors: Jake AXFORD, Rohan Eric John BECKWITH, Simone BONAZZI, Nicole BUSCHMANN, Artiom CERNIJENKO, Janetta DEWHURST, Aleem FAZAL, Matthew James HESSE, Lauren HOLDER, Viktor HORNAK, Hidetomo IMASE, Rama JAIN, Xianming JIN, John Ryan KERRIGAN, Julie LACHAL, Fupeng MA, Hasnain Ahmed MALIK, James R. MANNING, Daniel MCKAY, Robert Joseph MOREAU, Pierre NIMSGERN, Gary O'BRIEN, Anna VULPETTI, Ken YAMADA, Junping ZHAO
  • Publication number: 20220041610
    Abstract: The invention provides compounds of Formula (I): as further described herein, as well as pharmaceutical compositions comprising such compounds, and methods to use the compounds and pharmaceutical compositions for treatment of certain viral disorders, including influenza.
    Type: Application
    Filed: July 13, 2021
    Publication date: February 10, 2022
    Inventors: Rama JAIN, Dennis Christofer KOESTER, James R. MANNING, Vanessa MARX, Daniel POON, James Clifford SUTTON, Benjamin R. TAFT, Lifeng WAN, Aregahegn YIFRU, Qian ZHAO
  • Publication number: 20210079015
    Abstract: The invention provides compounds of Formula (I) n R3b Z W Q R3a H Y N R1 R4 R2 O (I) as described herein, along with stereoisomeric forms salts, hydrates, solvates, and salts thereof and pharmaceutical compositions and pharmaceutical combinations containing such compounds, as well as methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus (HBV), and for reducing the occurrence of serious conditions associated with HBV.
    Type: Application
    Filed: November 16, 2018
    Publication date: March 18, 2021
    Inventors: Jiping FU, Mika LINDVALL, James R. MANNING, Glenn MCENROE
  • Publication number: 20200407365
    Abstract: The invention provides compounds of Formula (I), as described herein, along with stereoisomeric forms salts, hydrates, solvates, and salts thereof and pharmaceutical compositions and pharmaceutical combinations containing such compounds, as well as methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus (HBV), and for reducing the occurrence of serious conditions associated with HBV.
    Type: Application
    Filed: February 26, 2019
    Publication date: December 31, 2020
    Inventors: Jiping FU, Rama JAIN, Xianming JIN, Xiaodong LIN, Mika LINDVALL, James R. MANNING, Glenn MCENROE
  • Publication number: 20200407366
    Abstract: The invention provides compounds of Formula (I): as further described herein, as well as pharmaceutical compositions comprising such compounds, and methods to use the compounds and pharmaceutical compositions for treatment of certain viral disorders, including influenza.
    Type: Application
    Filed: February 26, 2019
    Publication date: December 31, 2020
    Inventors: Maxime DAUPHINAIS, Rama JAIN, Dennis Christofer KOESTER, James R. MANNING, Vanessa MARX, Daniel POON, Lifeng WAN, Xiaojing Michael WANG, Aregahegn YIFRU, Qian ZHAO
  • Publication number: 20200347072
    Abstract: The present invention provides a compound of Formula (I) including pharmaceutically acceptable salts thereof: (I) and therapeutic uses of these compounds. The invention further provides pharmaceutical compositions comprising these compounds, compositions comprising these compounds with a therapeutic co-agent, and methods of using the compounds and compositions to treat viral infections.
    Type: Application
    Filed: July 20, 2020
    Publication date: November 5, 2020
    Inventors: Rama JAIN, Dennis Christofer KOESTER, James R. MANNING, James Clifford SUTTON, Benjamin Robert TAFT, Lifeng WAN, Qian ZHAO
  • Publication number: 20200123167
    Abstract: The invention provides compounds of Formula (I): as further described herein, as well as pharmaceutical compositions comprising such compounds, and methods to use the compounds and pharmaceutical compositions for treatment of certain viral disorders, including influenza.
    Type: Application
    Filed: August 25, 2017
    Publication date: April 23, 2020
    Inventors: Rama JAIN, Dennis Christofer KOESTER, James R. MANNING, Vanessa MARX, Daniel POON, James Clifford SUTTON, Benjamin Robert TAFT, Lifeng WAN, Aregahegn YIFRU, Qian ZHAO
  • Publication number: 20190092780
    Abstract: The present invention provides a compound of Formula (I) including pharmaceutically acceptable salts thereof: and therapeutic uses of these compounds. The invention further provides pharmaceutical compositions comprising these compounds, compositions comprising these compounds with a therapeutic co-agent, and methods of using the compounds and compositions to treat viral infections.
    Type: Application
    Filed: March 7, 2017
    Publication date: March 28, 2019
    Inventors: Rama JAIN, Dennis Christofer KOESTER, James R. MANNING, James Clifford SUTTON, Benjamin Robert TAFT, Lifeng WAN, Qian ZHAO
  • Publication number: 20180057501
    Abstract: The invention provides compounds of Formula (I): as further described herein, as well as pharmaceutical compositions comprising such compounds, and methods to use the compounds and pharmaceutical compositions for treatment of certain viral disorders, including influenza.
    Type: Application
    Filed: August 25, 2017
    Publication date: March 1, 2018
    Inventors: Rama JAIN, Dennis Christofer KOESTER, James R. MANNING, Vanessa MARX, Daniel POON, James Clifford SUTTON, Benjamin R. TAFT, Lifeng WAN, Aregahegn YIFRU, Qian ZHAO
  • Publication number: 20180051015
    Abstract: The invention is directed to a formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b and R3-R7 are herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.
    Type: Application
    Filed: April 27, 2017
    Publication date: February 22, 2018
    Inventors: Thomas Raymond CAFERRO, Zhuoliang CHEN, Young Shin CHO, Abran Q. COSTALES, Julian Roy LEVELL, Gang LIU, James R. MANNING, Martin SENDZIK, Cynthia SHAFER, Michael David SHULTZ, James Clifford SUTTON, Yaping WANG, Qian ZHAO
  • Publication number: 20170267673
    Abstract: The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A4, A5, A6, A8, and each of Ra, Rb, R1, R2, R3 and R7 of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas II and III, and sub-formula embodiments thereof, intermediates and methods for preparing compounds of the invention.
    Type: Application
    Filed: November 17, 2016
    Publication date: September 21, 2017
    Applicant: AMGEN INC.
    Inventors: Jennifer R. ALLEN, Albert AMEGADZIE, Matthew P. BOURBEAU, James A. BROWN, Jian J. CHEN, Yuan CHENG, Michael J. FROHN, Angel GUZMAN-PEREZ, Paul E. HARRINGTON, Longbin LIU, Qingyian LIU, Jonathan D. LOW, Vu Van MA, James R. MANNING, Ana Elena MINATTI, Thomas T. NGUYEN, Nobuko NISHIMURA, Mark H. NORMAN, Liping H. PETTUS, Alexander J. PICKRELL, Wenyuan QIAN, Shannon RUMFELT, Robert M. RZASA, Aaron C. SIEGMUND, Markian M. STEC, Ryan D. WHITE, Qiufen XUE
  • Publication number: 20160318915
    Abstract: The invention is directed to a formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b and R3-R7 are herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.
    Type: Application
    Filed: July 13, 2016
    Publication date: November 3, 2016
    Applicant: NOVARTIS AG
    Inventors: Thomas Raymond CAFERRO, Zhuoliang CHEN, Young Shin CHO, Abran Q. COSTALES, Julian Roy LEVELL, Gang LIU, James R. MANNING, Martin SENDZIK, Cynthia SHAFER, Michael David SHULTZ, James Clifford SUTTON, Yaping WANG, Qian ZHAO
  • Publication number: 20140275083
    Abstract: The invention is directed to a formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b and R3-R7 are herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.
    Type: Application
    Filed: March 13, 2014
    Publication date: September 18, 2014
    Applicant: NOVARTIS AG
    Inventors: Thomas Raymond CAFERRO, Zhuoliang CHEN, Young Shin CHO, Abran Q. COSTALES, Julian Roy LEVELL, Gang LIU, James R. MANNING, Martin SENDZIK, Cynthia SHAFER, Michael David SHULTZ, James SUTTON, Yaping WANG, Qian ZHAO